DelveInsight’s ‘Diabetes Pipeline Insight 2022‘ report provides comprehensive global coverage of available, marketed, and pipeline Diabetes therapies in various stages of clinical development, major pharmaceutical companies are working to advance the pipeline space and future growth potential of the Diabetes pipeline domain.
For Diabetes emerging drugs, the Diabetes pipeline analysis report provides a 360° view of the therapeutics landscape by development point, product type, route of administration, molecule type, and MOA. The Diabetes pipeline research covers business opportunities, challenges, future partnerships, strong competitors, and growth strategies.
Key takeaways from the Diabetes Pipeline Report
- Over 200+ Diabetes pipeline therapies are in various stages of development, and their anticipated acceptance in the Diabetes market would significantly increase market revenue.
- The leading Diabetes Companies developing novel drug candidates to improve the diabetes treatment landscape include Daewoong Tradipitant, Janssen Biotech, Zealand Pharma, Provention Bio, BioRestorative Therapies, Elevian, Kamada, Adocia, Oramed Pharmaceuticals, ImCyse, Histogen, Novo Nordisk, Enthera, ActoBio Therapeutics, Japan Tobacco, Avotres, and others.
- Promising Diabetes Pipeline therapies in various stages of development include LY2963016, Drug: Lantus, Drug: OAMs, Drug: insulin glargine + exenatide + preexisting metformin, Drug: insulin glargine + sitagliptin + preexisting metformin, Drug: insulin glargine + preexisting metformin, ORMD-0801, Cotadutide, and others.
- The Diabetes Companies and academics are working to assess challenges and seek opportunities that could influence R&D Diabetes. The Diabetes pipeline therapies under development are focused on novel approaches to treat/improve Diabetes.
Request a sample and discover the recent breakthroughs happening in Diabetes pipeline landscape @ Diabetes Pipeline Outlook Report
Diabetes Overview
Diabetes is a chronic disease that occurs when the pancreas does not produce enough insulin or alternatively, when the body cannot effectively use the insulin it produces. The vast majority of Diabetes can be classified as either type 1 or type 2 diabetes. Type 1 diabetes is an autoimmune disease is characterized by a lack of insulin production by the pancreas. Type 2 diabetes occurs when body becomes resistant to insulin, and sugar builds up in the blood. About 90% of people with diabetes around the world have type 2. It is largely the result of excess body weight and physical inactivity. Diabetes can cause a heart attack, stroke, blindness, kidney disease, nerve damage, and other serious health problems.
Find out more about the diagnosis and treatment of patients with Diabetes @ Diabetes Treatment Landscape
Diabetes Emerging Drugs Profile
- Enavogliflozin – Daewoong
Enavogliflozin (DWP 16001) is an orally available small molecule and sodium glucose transporter 2 inhibitor. The molecule is in phase-3 clinical trials for type-2 diabetic treatment. Enavogliflozin demonstrates the lowering of blood sugar and safety in diabetic patients in phase 2 clinical trials.
- Golimumab – Janssen Biotech
Golimumab is a human IgG1 monoclonal antibody, derived from immunizing genetically engineered mice with human TNFα. It inhibits soluble and transmembrane forms of TNF-α by binding to their specific receptors and blocking in consequence their bioactivity. It is currently under Phase II development for the treatment of Type 1 diabetes mellitus.
Diabetes Pipeline Therapies and Key Companies
- Daewoong Tradipitant: LY2963016
- Janssen Biotech: Lantus
- Zealand Pharma: OAMs
- Provention Bio: insulin glargine
- BioRestorative Therapies: exenatide
- Elevian: preexisting metformin
- Kamada: insulin glargine
- Adocia: sitagliptin
- Oramed Pharmaceuticals: preexisting metformin
- ImCyse: insulin glargine
- Histogen: preexisting metformin
- Novo Nordisk: ORMD-0801
- Enthera: Cotadutide
Learn more about the Diabetes Emerging pipeline therapies @ Diabetes Ongoing Clinical Trials Analysis
Diabetes Pipeline Therapeutic Assessment
Phases
- Late stage products (Phase III)
- Mid-stage products (Phase II)
- Early-stage product (Phase I) along with the details of
- Pre-clinical and Discovery stage candidates
- Discontinued & Inactive candidates
- Route of Administration
Route of Administration
- Oral
- Parenteral
- intravitreal
- Subretinal
- Topical.
- ·Molecule Type
Molecule Types
- Monoclonal Antibody
- Peptides
- Polymer
- Small molecule
- Gene therapy
- Product Type
Scope of the Diabetes Pipeline Report
- Coverage- Global
- Diabetes Companies- Daewoong Tradipitant, Janssen Biotech (JNJ: NYSE), Zealand Pharma (NYSE: ZLDPF), Provention Bio (NYSE: PRVB), BioRestorative Therapies (NYSE: BRTX), Elevian, Kamada (NYSE: KMDA), Adocia (NYSE: ADOC), Oramed Pharmaceuticals (NYSE: ORMP), ImCyse, Histogen (NYSE: HSTO), Novo Nordisk (NYSE: NVO), Enthera Bio (NYSE: ENTX), ActoBio Therapeutics, Japan Tobacco (NYSE: JAPAF), Avotres, and others.
- Diabetes Pipeline Therapies- LY2963016, Drug: Lantus, Drug: OAMs, Drug: insulin glargine + exenatide + preexisting metformin, Drug: insulin glargine + sitagliptin + preexisting metformin, Drug: insulin glargine + preexisting metformin, ORMD-0801, Cotadutide, and others.
Dive deep into rich insights for Diabetes Emerging Therapies and assessment; visit @ Diabetes Emerging Therapies
Table of Content
- Introduction
- Executive Summary
- Diabetes: Overview
- Diabetes Pipeline Therapeutics
- Diabetes Therapeutic Assessment
- Diabetes – DelveInsight’s Analytical Perspective
- In-depth Commercial Assessment
- Diabetes Collaboration Deals
- Late Stage Products (Phase III)
- Enavogliflozin: Daewoong
- Mid Stage Products (Phase II)
- Golimumab: Janssen Biotech
- Drug profiles in the detailed report…..
- Early Stage Products (Phase II/I)
- IMCY-0098: ImCyse
- Drug profiles in the detailed report…..
- Pre-clinical and Discovery Stage Products
- ENT-001: Enthera
- Inactive Products
- Diabetes Key Companies
- Diabetes Key Products
- Diabetes Unmet Needs
- Diabetes Market Drivers
- Diabetes Market Barriers
- Diabetes Future Perspectives and Conclusion
- Diabetes Analyst Views
- Diabetes Key Companies
- Appendix
For further information on the Diabetes Pipeline therapeutics, reach out @ Diabetes Companies & Pipeline Therapies
Latest Market Research Reports 2022 by DelveInsight
Brucellosis Market | Medical Marijuana Market | Opioid-related Disorders Market | Oncolytic Virus Cancer Therapy Pipeline | Anti-Neutrophil Cytoplasmic Antibody-Associated Vasculitis Market Insight, Epidemiology And Market | Oral Electrolyte Solutions Market | Stem Cell Market | Erosive Hand Osteoarthritis Market | Propionic Acidemia Market | Superficial Punctate Keratitis Market
Latest Blogs by DelveInsight
- Key Insights and Analysis Into the Point of Care Diagnostics Market
- Nascent Advancements and Emerging Therapies in Chronic Pulmonary Hypertension Treatment Market
About Us
DelveInsight is a Business Consulting and Market research company, providing expert business solutions for the healthcare domain and offering quintessential advisory services in the areas of R&D, Strategy Formulation, Operations, Competitive Intelligence, Competitive Landscaping, and Mergers & Acquisitions.
Contact Us
Yash Bhardwaj